Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute
Monday, 11 February 2019 Zelda Therapeutics Ltd (ASX:ZLD) has engaged the International Cannabis and Cannabinoids Institute (ICCI) to support its clinical trial programs in autism, opioid reduction and insomnia. This provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts. The ICCI is an international centre of excellence for the advancement of cannabis and cannabinoid treatments. The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators. READ: Zelda Therapeutics on track to report on multiple clinical trials Zelda’s managing director Dr Richard Hopkins said “We’re honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programs. “Dr Russo and the ICCI will complement our existing medical advisory team and maintains Zelda’s strategy of engaging the world’s best medicinal cannabis researchers and clinicians.” Dr Ethan Russo was recently appointed the Director of Research and Development at the ICCI. He is a US-trained board-certified paediatric and adult neurologist, psychopharmacology researcher, former Senior Medical Advisor to GW Pharmaceuticals, and Medical Director of PHYTECS. Dr Russo said: “I’m delighted to be collaborating with Zelda who is at the forefront of efforts to develop plant-derived cannabis medicines that have the potential to improve quality of life for patients.” Progressing clinical and pre-clinical activities in 2019 Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019. The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives. Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.
Don't be surprised about Constellation's investment in Canopy Growth , says Jim Cramer. Constellation Brands invested over $4 billion in cannabis company Canopy Growth. The investment also means that the two companies will be working closely together to produce cannabis-infused beverages. Back in...
Jim Cramer says that, while Real Money Stock of the Day Aurora Cannabis bringing on Nelson Peltz as an adviser is the right move, typically it's who puts money into the cannabis company that matters. ..
Happy hump day! Here are the headlines that Jim Cramer is looking at Wednesday. President Trump's Sit Down With Kim Jong Un President Trump sat down with North Korea's Kim Jong Un Wednesday morning in..
According to Business Insider, "Cannabis producer Aurora Cannabis beat on the top line. The company said its margins were lower as production costs jumped and prices fell." CEO Terry Booth in a press..